MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 11.1% from a year ago
Cash & equivalents stood at $55.71M at the end of Q1 FY2026, up 11.1% from a year earlier and up 19.2% from the prior quarter. Over 3 fiscal years it compounded at +19.1% a year.
Context
- Cash & equivalents amounted to 13.3% of total assets at the end of Q1 FY2026, down 31.7 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +11.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 46.73M USD
- Year-over-year change
- +22.2%
- 3-year CAGR
- +19.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.73M | +22.2% |
| FY2024 | 2024-12-31 | 38.25M | -52.0% |
| FY2023 | 2023-12-31 | 79.77M | +188.3% |
| FY2022 | 2022-12-31 | 27.67M | — |
Cash & Equivalents vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 cash & equivalents of $55.71M is the lowest of the 11 companies compared; the peer median is $194.11M.
- Its year-over-year change of +11.1% is the 9th highest of 11, against a peer median of +110.0%.
- Cash & equivalents amounts to 13.3% of total assets for MPLT, versus a peer median of 61.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $24.65B | +161575.2% | +31.6% | 25.9% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $320.68M | +2154.3% | +126.9% | 81.5% |
| Mar 2026 | $263.76M | +64.1% | +54.0% | 95.5% | |
| Mar 2026 | $242.65M | -0.9% | +14.1% | 88.2% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $241.15M | +1108.2% | +22.0% | 22.4% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $147.07M | +15.9% | -8.8% | 95.6% |
| Dec 2025 | $131.75M | +9.1% | -11.7% | 99.1% | |
| Mar 2026 | $95.6M | +156.0% | -1.6% | 34.3% | |
| Mar 2026 | $94.06M | +345.0% | -33.6% | 41.7% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $78.06M | +35.5% | +19.1% | 15.7% |
| Mar 2026 | $55.71M | +11.1% | +19.1% | 13.3% | |
| Peer median (excluding MPLT) | $194.11M | +110.0% | +16.6% | 61.6% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.